The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 Mar 2020 07:49

RNS Number : 5885G
4d Pharma PLC
18 March 2020
 

 

 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

Name

Shares in 4D pharma plc before purchase

% of total shares in issue

Shares in 4D pharma plc after purchase

% of total shares in issue

David Norwood (Chairman)

8,457,061

7.7%

 8,557,061

7.8%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Norwood

2

Reason for the notification

a)

Position/status

Chairman/ PDMR

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

4D Pharma plc

b)

LEI

213800O49VYSXWE2ZD52

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

28p

100,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

Date of the transaction

17th March 2020

f)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information please contact:

4D

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXDPFLKEEEA
Date   Source Headline
9th Nov 20201:00 pmRNSSITC data MRx0518 monotherapy and combination
5th Nov 202012:00 pmRNSVirtual KOL Event SITC Data
30th Oct 20204:57 pmRNSHolding(s) in Company
23rd Oct 20201:17 pmRNSHolding(s) in Company
22nd Oct 20207:00 amRNSProposed Merger & Intention to seek NASDAQ Listing
14th Oct 202010:09 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSPresentations on MRx0518 at SITC 2020
12th Oct 20202:01 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSTopline Results for Blautix phase II trial
30th Sep 20207:00 amRNSInterim Results
23rd Sep 20207:00 amRNSDirectorate Change
14th Sep 20204:30 pmRNSBlock Listing Six Monthly Return
7th Sep 20205:26 pmRNSHolding(s) in Company
1st Sep 20204:58 pmRNS4D hosts virtual R&D event
26th Aug 20207:00 amRNSMRx0158 Keytruda Part A clinical benefit data
14th Aug 20204:49 pmRNSHolding(s) in Company
12th Aug 20207:00 amRNSHolding(s) in Company
28th Jul 202010:34 amRNSHolding(s) in Company
24th Jul 20204:58 pmRNSHolding(s) in Company
20th Jul 20205:09 pmRNSHolding(s) in Company
16th Jul 20206:15 pmRNSHolding(s) in Company
16th Jul 20204:43 pmRNSHolding(s) in Company
15th Jul 20204:16 pmRNSHolding(s) in Company
13th Jul 20205:57 pmRNSResult of Fundraising
13th Jul 202012:13 pmRNSPlacing and Subscription of £7.7m
6th Jul 20207:00 amRNSOncology Clinical Update
2nd Jul 20204:02 pmRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCOVID-19 study open for enrolment
30th Jun 20201:05 pmRNSResult of AGM
25th Jun 20207:00 amRNSHolding(s) in Company
22nd Jun 202011:19 amRNSHolding(s) in Company
10th Jun 20205:25 pmRNSHolding(s) in Company
10th Jun 20205:17 pmRNSHolding(s) in Company
10th Jun 202011:21 amRNSHolding(s) in Company
5th Jun 20201:00 pmRNSAnnual Report and Notice of AGM
5th Jun 20207:41 amRNS4D hosts virtual R&D event
26th May 20207:00 amRNSFinal Results
21st May 20207:00 amRNSDirectorate Change
19th May 20206:20 pmRNSHolding(s) in Company
12th May 20206:06 pmRNSHolding(s) in Company
11th May 20207:00 amRNSCompletion of immuno-oncology study safety phase
24th Apr 202011:30 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSPhase II study in COVID-19
17th Apr 20207:00 amRNSAppointment of Non-Executive Chairperson
17th Apr 20207:00 amRNSInterim analysis of Blautix phase II study data
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:03 pmRNSPrice Monitoring Extension
19th Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20209:47 amRNSHolding(s) in Company
18th Mar 20204:44 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.